HamptonRock Launches Transaction Advisory and CFO Services Practice
Daniel Villarreal, Philip Fritsche, and Ryan Bailey join HamptonRock to lead the growth and development…
Daniel Villarreal, Philip Fritsche, and Ryan Bailey join HamptonRock to lead the growth and development…
Easy-to-use eyewear retail solution captures customers’ precise facial measurements to fit frames and elevate the…
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage…
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage…
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild…
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild…
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Portal provides resources to raise awareness around mental health and suicide prevention MALVERN, Pa., Sept….
Portal provides resources to raise awareness around mental health and suicide prevention MALVERN, Pa., Sept….
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO…
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO…
GelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security…
GelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security…
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a…
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a…
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment…
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment…